文献速递糖尿病

糖尿病相关突变胰岛素p.R46Q(GlnB22-胰岛素)的体内测定与生物学特征

In vivo measurement and biological characterisation of the diabetes-associated mutant insulin p.R46Q (GlnB22-insulin).
PubMed 文献 · Diabetologia · 2017-05-06

研究一名携带胰岛素基因p.R46Q(GlnB22-胰岛素)突变的18岁MODY女性,用LC-MS测定口服葡萄糖耐量试验中突变型与野生型胰岛素的分泌,并结合INS-1细胞体外研究。结果显示GlnB22-胰岛素浓度在各时间点为野生型的1.5倍,受体亲和力为野生型的57%,体外表达p.R46Q-胰岛素与胰岛素分泌减少相关,但未诱导内质网应激。

要点

  • OGTT各时间点血浆GlnB22-胰岛素浓度为野生型胰岛素的1.5倍。
  • GlnB22-胰岛素对人胰岛素受体的亲和力为野生型的57%。
  • INS-1细胞表达p.R46Q-胰岛素与胰岛素分泌减少相关,但未诱导内质网应激。

核心结论

  • β细胞在体内和体外均能加工并分泌GlnB22-胰岛素。
  • 突变蛋白能够被加工和分泌可能预示胰岛素突变相关糖尿病病程更为良性。
  • 当β细胞因胰岛素需求增加而处于应激状态时糖尿病发生,如其他影响胰岛素原加工为胰岛素或降低胰岛素受体亲和力的胰岛素突变个体中所见。

研究设计与样本

  • 对一名携带胰岛素突变p.R46Q(GlnB22-胰岛素)的18岁MODY女性进行标准75 g OGTT,并用LC-MS测定野生型与突变型胰岛素。
  • 在大鼠INS-1胰岛素瘤细胞中体外研究p.R46Q-胰岛素的合成与分泌。
  • 在表达人胰岛素受体的幼仓鼠肾(BHK)细胞上检测GlnB22-胰岛素的受体亲和力。

主要发现

  • OGTT各时间点血浆GlnB22-胰岛素浓度为野生型胰岛素的1.5倍。
  • GlnB22-胰岛素对人胰岛素受体的亲和力为野生型胰岛素的57%。
  • INS-1细胞表达p.R46Q-胰岛素与胰岛素分泌减少相关,但未诱导内质网应激。

临床怎么用

  • 作者认为,联合免疫沉淀与LC-MS测定突变型与野生型胰岛素的方法可能有助于研究其他突变胰岛素蛋白。
  • 作者认为,突变蛋白能够被加工和分泌可能预示胰岛素突变相关糖尿病病程更为良性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Heterozygous mutations in the insulin gene that affect proinsulin biosynthesis and folding are associated with a spectrum of diabetes phenotypes, from permanent neonatal diabetes to MODY. In vivo studies of these mutations may lead to a better understanding of insulin mutation-associated diabetes and point to the best treatment strategy. We studied an 18-year-old woman with MODY heterozygous for the insulin mutation p.R46Q (GlnB22-insulin), measuring the secretion of mutant and wild-type insulin by LC-MS. The clinical study was combined with in vitro studies of the synthesis and secretion of p.R46Q-insulin in rat INS-1 insulinoma cells. METHODS: We performed a standard 75 g OGTT in the 18-year-old woman and measured plasma glucose and serum insulin (wild-type insulin and GlnB22-insulin), C-peptide, proinsulin, glucagon and amylin. The affinity of GlnB22-insulin was tested on human insulin receptors expressed in baby hamster kidney (BHK) cells. We also examined the subcellular localisation, secretion and impact on cellular stress markers of p.R46Q-insulin in INS-1 cells. RESULTS: Plasma GlnB22-insulin concentrations were 1.5 times higher than wild-type insulin at all time points during the OGTT. The insulin-receptor affinity of GlnB22-insulin was 57% of that of wild-type insulin. Expression of p.R46Q-insulin in INS-1 cells was associated with decreased insulin secretion, but not induction of endoplasmic reticulum stress. CONCLUSIONS/INTERPRETATION: The results show that beta cells can process and secrete GlnB22-insulin both in vivo and in vitro. Our combined approach of immunoprecipitation and LC-MS to measure mutant and wild-type insulin may be useful for the study of other mutant insulin proteins. The ability to process and secrete a mutant protein may predict a more benign course of insulin mutation-related diabetes. Diabetes develops when the beta cell is stressed because of increased demand for insulin, as observed in individuals with other insulin mutations that affect the processing of proinsulin to insulin or mutations that reduce the affinity for the insulin receptor.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Støy J, Olsen J, Park SY, et al. In vivo measurement and biological characterisation of the diabetes-associated mutant insulin p.R46Q (GlnB22-insulin). Diabetologia. 2017. PMID: 28478482. doi:10.1007/s00125-017-4295-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。